Last reviewed · How we verify
Mycophenylate mofetil
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection. Used for Prevention of organ transplant rejection (renal, cardiac, hepatic), Autoimmune conditions including lupus nephritis and other systemic autoimmune diseases.
At a glance
| Generic name | Mycophenylate mofetil |
|---|---|
| Also known as | MMF, MMF, Cellcept, CellCept |
| Sponsor | Masonic Cancer Center, University of Minnesota |
| Drug class | Immunosuppressant, IMPDH inhibitor |
| Target | Inosine monophosphate dehydrogenase (IMPDH) type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
MMF is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant form in activated lymphocytes. This blocks guanosine nucleotide synthesis required for lymphocyte DNA replication, thereby suppressing T cell and B cell proliferation while having minimal effects on other cell types. It is used as an immunosuppressant to prevent organ transplant rejection and in autoimmune conditions.
Approved indications
- Prevention of organ transplant rejection (renal, cardiac, hepatic)
- Autoimmune conditions including lupus nephritis and other systemic autoimmune diseases
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)
- Leukopenia
- Anemia
- Infection
- Headache
- Tremor
- Hypertension
Key clinical trials
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NA)
- Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- RituxiMab INDuction in Renal Transplantation (PHASE4)
- HSCT for High Risk Inherited Inborn Errors (PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies (PHASE2)
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD (PHASE2)
- Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenylate mofetil CI brief — competitive landscape report
- Mycophenylate mofetil updates RSS · CI watch RSS
- Masonic Cancer Center, University of Minnesota portfolio CI